What Диане-35 Treats: Main Uses and Benefits

Диане-35 is authorized for the treatment of certain hormone-related skin conditions in women of reproductive age. The main uses are focused on managing signs of androgenization, which are physical changes in women caused by the effects of male sex hormones (androgens).

Key therapeutic applications include:

• Severe Acne: Treatment of moderate to severe acne when alternative treatments, such as topical therapy or systemic antibiotic treatments, have been unsuccessful.
• Hirsutism: Management of mild to moderate excessive, unwanted growth of terminal hair on the face and body. This is used in cases where no underlying cause for the hair growth has been identified.

When prescribed for these conditions, a key benefit is the reliable contraceptive coverage it provides, preventing pregnancy while the patient is undergoing treatment for the skin conditions. However, the medicine should not be prescribed for the purpose of contraception alone.

---

Quick Facts

• Condition Managed: Severe acne, following failure of other treatments.
• Condition Managed: Mild to moderate hirsutism (excessive hair growth).

Official Eligibility and Contraindications for Диане-35

The eligibility for Диане-35 is strictly defined by regulatory documents, emphasizing its use in specific patient populations while prohibiting it in high-risk individuals. It is authorized for women of reproductive age for the treatment of moderate to severe acne or hirsutism after other treatments have failed. It is explicitly not indicated for use as a contraceptive method alone.

Category	Official Regulatory Statement
Contraindications	Current or history of venous or arterial thromboembolism (VTE/ATE), diagnosed clotting disorders, severe hepatic disease, history of liver tumours, hormone-influenced malignancies (e.g., breast cancer), or migraine with focal neurological symptoms.
Age Restriction	The medicine is only indicated after menarche and is not indicated for use in post-menopausal women.
Pregnancy Status	Contraindicated in known or suspected pregnancy and is not recommended during lactation/breastfeeding.
Co-use Restriction	Must not be used in combination with any other hormonal contraceptive.

These guidelines establish clear boundaries for safe use, primarily excluding individuals with significant vascular, hepatic, or malignant risk factors, and limiting its use to the approved androgen-related conditions.

The official interaction profile for Диане-35 is structured by mandatory regulatory restrictions concerning co-administration. The combination of Cyproterone Acetate and Ethinyl Estradiol is strictly contraindicated for use with any other hormonal contraceptive and with certain Direct-Acting Antivirals (DAAs) for Hepatitis C, such as products containing Ombitasvir, Paritaprevir, or Dasabuvir.

Most documented interactions are pharmacokinetic, resulting in changes to plasma concentrations. Co-administration with potent enzyme-inducing medicines, including the antibacterial Rifampicin and certain anticonvulsants (e.g., Phenytoin, Carbamazepine), officially decreases the plasma levels and increases the clearance of the hormonal components. This effect is also documented for the herbal product St John's Wort. Conversely, enzyme inhibitors like Ketoconazole and Clarithromycin officially increase the exposure of the hormonal components by reducing their clearance.

The medicine also modifies the exposure of other drugs. Its co-administration is officially documented to increase the plasma concentration of medicines such as the immunosuppressant Ciclosporin and Tizanidine. Furthermore, a pharmacodynamic interaction is documented in which the efficacy of co-administered antidiabetic agents may be officially decreased. A final, interaction-related constraint is that the medicine is contraindicated in women with severe hepatic disease due to significantly altered hormonal clearance, which increases exposure risk.

The Pharmacodynamics of Диане-35

Диане-35 contains cyproterone acetate (CPA) and ethinyl estradiol (EE). CPA functions as a competitive antagonist at the androgen receptor (AR) in target tissues, including the sebaceous glands and hair follicles. This interaction physically blocks the binding of endogenous androgens, such as testosterone and dihydrotestosterone (DHT), thereby inhibiting the androgen-mediated gene transcription and subsequent cellular effects.

Simultaneously, CPA exhibits a progestogenic activity, and the combination with EE utilizes a negative feedback mechanism on the hypothalamic-pituitary-ovarian (HPO) axis. This suppression reduces the pulsatile release of gonadotropin-releasing hormone (GnRH), leading to a decreased secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary. This diminished gonadotropin signaling arrests follicular development and prevents the LH surge, which inhibits ovulation (anovulation) and reduces endogenous ovarian androgen synthesis.

Furthermore, EE acts on the liver, increasing the synthesis of sex hormone-binding globulin (SHBG). This rise in SHBG plasma concentration results in increased binding of circulating free androgens, effectively lowering the systemic levels of bioavailable androgens. The convergent actions of AR antagonism, HPO axis suppression, and reduced free androgen availability collectively modulate the systemic hormonal environment.

Диане-35 is formulated for oral use as a coated tablet, which is the only authorized administration route. Each active tablet contains the fixed combination dose of 2 mg Cyproterone Acetate and 0.035 mg Ethinyl Estradiol. The administration follows a strict cyclic regimen composed of a 28-day course, where one tablet is taken daily for 21 consecutive days, immediately followed by a 7-day interval without tablet intake.

To establish the necessary systemic levels, the medicine must be taken at approximately the same time every day. For initiating the first course, the tablet-taking should commence on Day 1 of the menstrual cycle. During the course, if a tablet is delayed by less than 12 hours, the tablet should be taken immediately. The concurrent use of Диане-35 with any other hormonal contraceptive preparation is prohibited.

The overall duration of use is governed by the clinical objective; the standard usage pattern involves continuation for several months. Treatment is recommended to be withdrawn 3 to 4 cycles after the treated condition’s clinical signs have completely resolved. Usage is restricted in populations with severe hepatic impairment, and the product is generally not recommended for use in patients under 18 years of age.

Research evidence / Overview of studies for Диане-35

Evidence for Use in Severe Acne

The research base for this use includes multiple Randomized Controlled Trials (RCTs) and comparative studies, primarily used in research exploring how symptoms change over time. These trials focused on women with moderate to severe acne, often selecting patients whose condition had not responded sufficiently to prior standard treatments like oral antibiotics. Researchers monitored changes in total lesion counts and outcomes were documented using standardized acne grading scales. Findings describe changes observed in the studies where a shift in measured outcomes was observed after several months of observation. Research indicates that the observation of measured changes may be typically associated with a sustained period of treatment.

---

Evidence for Use in Mild to Moderate Hirsutism

Clinical research into the use of this medicine for excessive hair growth consists of RCTs and long-term observational studies, which were primarily applied in studies examining patient-reported experiences. Studies explored how symptoms evolved, applying standardized systems for objective scoring, such as the Ferriman-Gallwey score, and monitoring patient-reported outcomes describing perceived discomfort. Findings indicate that a sustained treatment period, typically at least six to twelve months, was necessary for these measured changes in hair scores to become noticeable. Data show patterns related to symptom recurrence, where patients who discontinued the medicine experienced a return of excessive hair growth.

---

Evidence in Specific Populations (e.g., PCOS)

The combination pill was studied for women with underlying hyperandrogenic conditions, such as Polycystic Ovary Syndrome (PCOS). For these specific populations, research examined temporary physiological imbalance by monitoring outcomes linked to the concentration of androgens. The findings describe group patterns where measured changes in hormonal biomarkers, such as a reduction in free testosterone, were observed during the study period. However, results apply only to the populations studied, and data for certain groups (such as younger adolescents) remain insufficient.

---

What Research Gaps Remain

Follow-up durations were limited in many initial comparative trials, meaning long-term effects are not fully established regarding sustained remission after cessation. Current research contributes to understanding symptom patterns, but comparative evidence is lacking against many newer standard therapies now used for acne and hirsutism. Overall, the evidence highlights what is known—and what is still uncertain—particularly concerning the long-term maintenance of the changes observed during the defined treatment time intervals.

Common questions about Диане-35 (FAQ)

Q: Will the medication's effectiveness change if I have vomiting or severe diarrhea?

Official product information states that if vomiting or severe diarrhea occurs within 3 to 4 hours after taking the tablet, the drug's absorption may be incomplete. This reduction in absorption can decrease the medication's overall efficacy.

Q: How long is Dian-35 generally taken, and is a break necessary after long-term use?

The duration of use is determined by the treated condition and clinical response, rather than a fixed time limit. Regulatory documents generally recommend continuing treatment for at least 3 to 4 cycles after the clinical signs of the treated condition have fully resolved. The total duration of use is generally determined during consultation with a healthcare professional.

Q: Can this medication affect my blood test results?

Yes, according to official labeling, hormonal contraceptives like this one can influence the results of certain laboratory tests. These may include tests for liver function, as well as those evaluating thyroid, adrenal, and renal functions.

Q: Can I take Dian-35 if I have diabetes?

Official regulatory documents state that this medication is contraindicated (must not be used) in people with severe diabetes that involves vascular changes (damage to blood vessels).

Q: Why is Dian-35 sometimes prescribed to men?

This medication is officially indicated only for the treatment of moderate to severe acne and/or excessive hair growth (hirsutism) in women of childbearing age. The official product labeling for this medication indicates its use only in women of childbearing age for the specified conditions, and not for use in men.

Q: Does Dian-35 affect cholesterol levels?

Official safety information indicates that estrogen/progestogen combinations may cause an increase in plasma lipoproteins, which include both cholesterol and triglycerides. Regulatory documents indicate that caution is generally advised when this medication is administered to individuals who already have high lipid levels (hyperlipoproteinemia).

Q: Can this medication cause high blood pressure (hypertension)?

An increase in blood pressure has been reported in users of this type of medication. Regulatory information indicates that monitoring blood pressure is generally recommended when taking this medication.

Q: Does Dian-35 increase the risk of other cancers besides liver cancer?

An observed increased risk of breast cancer and cervical cancer has been reported in women using combined hormonal contraceptives. However, the regulatory documents state it is not definitively known if this observation is due to the hormonal product itself or to other factors.

Q: Can I take Dian-35 if I have migraines without aura?

The medication is contraindicated if you have a history of migraine with focal neurological symptoms (aura). Should new or worsening headaches occur, regulatory information suggests consulting a healthcare professional for guidance.

Q: Does Dian-35 cause hair loss?

Although this medication is indicated for the treatment of excessive hair growth (hirsutism), hair loss ('loss of scalp hair') is listed as a potential adverse reaction in some official product information.

Q: Does Dian-35 affect body weight?

Changes in weight are listed in the official safety profile as a potential side effect associated with this medication. This includes both weight increases (listed as common) and weight decreases (listed as rare).

Q: What are the warning signs or symptoms of a blood clot (VTE or ATE)?

Symptoms of a serious blood clot (venous or arterial thromboembolism) documented in regulatory sources include: sudden severe swelling or pain in one leg, sudden chest pain or shortness of breath, or a sudden, severe headache with aura. Official information also lists sudden weakness or numbness on one side of the body or sudden trouble seeing, speaking, or walking.

Q: What is the background risk of VTE (Venous Thromboembolism) for women who are not on hormonal contraceptives?

For comparison, the background incidence of Venous Thromboembolism (VTE) in women who are not using combined oral contraceptives is estimated at 0.5 to 1 case per 10,000 women per year. This information serves to illustrate the background incidence rate documented in official sources.

Q: Can this medication help with menstrual pain (dysmenorrhea)?

Menstrual pain (dysmenorrhea) is listed as a possible side effect in some product information. However, official sources also note that a decrease in period pain has been documented as a potential benefit in other sources.

How to Store and Dispose of Diane-35

This section details the official regulatory requirements for storing and discarding Diane-35 (Cyproterone Acetate and Ethinylestradiol) tablets to maintain product stability and ensure environmental safety.

Official Storage Conditions

Requirement	Specific Condition
Temperature	Store below 25 C in a cool, dry place.
Protection	Must be kept away from excess heat, direct sunlight, and moisture.
Packaging	Keep the tablets in their original packet to maintain integrity.
Safety	Store out of the sight and reach of children.

Disposal Requirements

Expired or unused Diane-35 must be discarded according to local regulatory guidelines. Do not dispose of the tablets in general household waste or wastewater (e.g., flushing down the toilet). The medicine should be returned to a pharmacist for proper pharmaceutical waste management.